MX347355B - Diagnostico basado en troponina y en peptido natriuretico cerebral (bnp) de pacientes en riesgo y de causa de ataque. - Google Patents

Diagnostico basado en troponina y en peptido natriuretico cerebral (bnp) de pacientes en riesgo y de causa de ataque.

Info

Publication number
MX347355B
MX347355B MX2014003496A MX2014003496A MX347355B MX 347355 B MX347355 B MX 347355B MX 2014003496 A MX2014003496 A MX 2014003496A MX 2014003496 A MX2014003496 A MX 2014003496A MX 347355 B MX347355 B MX 347355B
Authority
MX
Mexico
Prior art keywords
stroke
troponin
cause
risk patients
based diagnosis
Prior art date
Application number
MX2014003496A
Other languages
English (en)
Other versions
MX2014003496A (es
Inventor
Hess Georg
Zdunek Dietmar
Horsch Andrea
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47049159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX347355(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014003496A publication Critical patent/MX2014003496A/es
Publication of MX347355B publication Critical patent/MX347355B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

La presente invención se refiere a un método para diferenciar de manera temprana sí un sujeto padece de ataque insquémico cardioembólico o de ataque isquémico no cardioembólico, caracterizado porque comprende determinar la cantidad de una troponina cardíaca en una muestra de un sujeto que padece de ataque isquémico, en donde la muestra ser ha obtenido no más de 6 horas después del comienzo de los síntomas del ataque isquémico.
MX2014003496A 2011-10-17 2012-10-17 Diagnostico basado en troponina y en peptido natriuretico cerebral (bnp) de pacientes en riesgo y de causa de ataque. MX347355B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11185421 2011-10-17
PCT/EP2012/070553 WO2013057135A1 (en) 2011-10-17 2012-10-17 Troponin and bnp based diagnosis of risk patients and cause of stroke

Publications (2)

Publication Number Publication Date
MX2014003496A MX2014003496A (es) 2014-07-14
MX347355B true MX347355B (es) 2017-04-24

Family

ID=47049159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003496A MX347355B (es) 2011-10-17 2012-10-17 Diagnostico basado en troponina y en peptido natriuretico cerebral (bnp) de pacientes en riesgo y de causa de ataque.

Country Status (12)

Country Link
US (4) US20140220604A1 (es)
EP (2) EP3088900B1 (es)
JP (2) JP6117805B2 (es)
KR (2) KR101950561B1 (es)
CN (2) CN105785053B (es)
AU (1) AU2012324967B2 (es)
BR (2) BR122021026652B1 (es)
CA (1) CA2846285C (es)
ES (2) ES2595028T3 (es)
MX (1) MX347355B (es)
SG (1) SG2014014559A (es)
WO (1) WO2013057135A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072500A1 (en) 2012-11-09 2014-05-15 Roche Diagnostics Gmbh Tnt based diagnosis of paroxysmal atrial fibrillation
WO2017051938A1 (ko) * 2015-09-23 2017-03-30 (주)바이오메트릭스 테크놀로지 심질환 바이오마커의 표준농도-감도 테이블에 의한 심질환의 진행상태 및 치료상태를 모니터링하는 방법 및 이를 위한 바이오칩
EP3359968B1 (en) 2015-10-05 2020-08-19 University of Pittsburgh - Of the Commonwealth System of Higher Education Development and parameter assessment for vertically aligned platinum wire aptasensor arrays for impedimetric detection of cardiac biomarkers
ES2817087T3 (es) * 2016-08-04 2021-04-06 Hoffmann La Roche ESM-1 (endocan) circulante en la evaluación de la fibrilación auricular
WO2018229051A1 (en) * 2017-06-13 2018-12-20 Roche Diagnostics Gmbh Fatty acid binding protein 3 for the assessment of atrial fibrillation (af)
KR102170826B1 (ko) * 2018-01-18 2020-10-27 사회복지법인 삼성생명공익재단 뇌졸중 진단 또는 예후예측용 바이오마커 및 이의 용도
JP7451499B2 (ja) * 2018-08-24 2024-03-18 エフ． ホフマン－ラ ロシュ アーゲー 心房細動の判定および脳卒中の予測のための循環ｆｇｆｂｐ－１（線維芽細胞成長因子結合タンパク質１）
CN114807356B (zh) * 2022-05-19 2025-02-28 苏州大学 一种nppb基因dna羟甲基化标志物、引物及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
WO1996037777A1 (en) * 1995-05-23 1996-11-28 Nelson Randall W Mass spectrometric immunoassay
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
DE19828466A1 (de) 1998-06-26 1999-12-30 Roche Diagnostics Gmbh Entstörung von Immunoassays durch Substanzen, die aus den Framework-Regionen von Antikörpern abgeleitet sind
US6709855B1 (en) 1998-12-18 2004-03-23 Scios, Inc. Methods for detection and use of differentially expressed genes in disease states
DE19902601A1 (de) 1999-01-23 2000-07-27 Roche Diagnostics Gmbh Verfahren und Vorrichtung zum Entnehmen analytischer Verbrauchsmittel aus einem Vorratsbehältnis
ES2275513T3 (es) 1999-05-17 2007-06-16 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh Propiedades neuroprotectoras de gdf-15, un miembro de la superfamilia de tgf-beta.
US7427490B2 (en) 2001-08-20 2008-09-23 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
EP1322957B1 (en) 2001-05-04 2009-08-12 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
US20030022870A1 (en) * 2001-06-01 2003-01-30 Victor Dzau Methods of treating cardiac disorders
US7262017B2 (en) * 2001-09-14 2007-08-28 Torrey Pines Institute For Molecular Studies Diagnostic markers for ischemia
US20030082153A1 (en) * 2001-10-22 2003-05-01 The Government Of The United States Of America Stem cells that transform to beating cardiomyocytes
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CA2511501A1 (en) 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
DE602005008497D1 (de) 2004-03-15 2008-09-11 Roche Diagnostics Gmbh Verwendung des BNP-Art und ANP-Art Peptiden für das Festsetzen der Gefahren von Herzgefäß- Komplikationen als Folge der Volumenüberlastung
WO2005103720A1 (en) * 2004-03-29 2005-11-03 Medstar Research Institute, Inc. Methods of diagnosing cardiovascular disease
DE102004023402A1 (de) * 2004-05-12 2005-12-08 Roche Diagnostics Gmbh Verfahren zur Erhöhung des dynamischen Messbereichs von auf spezifischen Bindereaktionen basierenden, insbesondere immunologischen Testelementen
US20090042780A1 (en) 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
US20060003338A1 (en) 2004-06-30 2006-01-05 Deng David X System and methods for the management and treatment of vascular graft disease
US20060166303A1 (en) * 2005-01-24 2006-07-27 Eberhard Spanuth Use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs
CN101120256A (zh) 2005-02-17 2008-02-06 霍夫曼-拉罗奇有限公司 Nt-原anp/nt-原bnp的比值用于诊断心功能障碍的用途
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
ES2273599B1 (es) * 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
EP1816477A1 (en) 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG The use of natriuretic peptides and placenta growth factor levels for risk stratification of individuals elected for cardiac stress testing
US7838250B1 (en) * 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
JP5496658B2 (ja) * 2006-05-25 2014-05-21 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脳卒中を処置する方法
EP1862805A1 (en) 2006-06-01 2007-12-05 University of Zürich The use of mrp 8/14 levels for discrimination of individuals at risk of acute coronary syndromes
CN106018820B (zh) 2006-08-04 2018-04-27 汉诺威医学院 根据gdf-15评价心脏介入风险的工具与方法
US8324162B2 (en) * 2006-08-08 2012-12-04 Mayo Foundation For Medical Education And Research Diuretic and natriuretic polypeptides lacking the blood pressure lowering property
US20080050749A1 (en) * 2006-08-17 2008-02-28 Ildiko Amann-Zalan Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
KR20150113216A (ko) 2006-12-05 2015-10-07 디코드 제네틱스 이에이치에프 심장성 부정맥의 위험 관리를 위한 유전적 마커
IS8576A (is) * 2006-12-05 2007-01-15 Decode Genetics Genetic susceptibility variants of atrial fibrillation and stroke
WO2008089994A1 (en) 2007-01-25 2008-07-31 Roche Diagnostics Gmbh Use of igfbp-7 in the assessment of heart failure
US20100197518A1 (en) * 2007-05-01 2010-08-05 Huichun Xu Methods for Diagnosing Ischemia
EP2037278A1 (en) * 2007-09-11 2009-03-18 F.Hoffmann-La Roche Ag Vascular markers in the remodelling of cardiac injury
EP2040072B1 (de) * 2007-09-22 2013-01-02 Roche Diagnostics GmbH Analysesystem zur Bestimmung der Konzentration eines Analyten in einer Körperflüssigkeit
EP2201383B1 (en) 2007-10-10 2014-01-15 Roche Diagnostics GmbH Means and methods for monitoring myocardial infarction and its treatment
EP2210111A1 (en) * 2007-10-10 2010-07-28 Roche Diagnostics GmbH Natriuretic peptide/troponin ratio for the assessment of preexisting myocardial dysfunction in patients with acute coronary syndrome
US20090233312A1 (en) * 2007-10-10 2009-09-17 Nanosphere, Inc. Methods and assays to assess cardiac risk and ischemia
RU2010133157A (ru) * 2008-01-07 2012-02-20 Орто-Клиникал Дайэгностикс, Инк. (Us) Определение комплекса sflt-1:ангиогенный фактор
EP2318844A1 (en) 2008-07-14 2011-05-11 Roche Diagnostics GmbH Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure
WO2010017972A1 (en) * 2008-08-13 2010-02-18 Roche Diagnostics Gmbh D-dimer, troponin, nt-probnp for pulmonary embolism
JP5902479B2 (ja) * 2008-10-24 2016-04-13 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング マーカーペプチドのレベルを決定することによる脳卒中患者における予後判定及びリスク評価のための方法
EP2425245B1 (en) 2009-04-27 2016-10-05 Roche Diagnostics GmbH Use of endostatin as a marker of heart failure
CN105548563B (zh) 2009-07-27 2017-09-22 霍夫曼-拉罗奇有限公司 mimecan在评价心力衰竭中的用途
EP2796874B1 (en) 2010-08-26 2017-03-08 Roche Diagnostics GmbH Use of biomarkers in monitoring a medication in a subject suffering from heart failure
ES2913539T3 (es) 2012-09-12 2022-06-02 Hoffmann La Roche Identificación de pacientes con fracción de acortamiento anómala
EP2730923A1 (en) 2012-11-09 2014-05-14 Roche Diagniostics GmbH NTproBNP and cTnT based therapy guidance in heart failure
CN108956999A (zh) 2012-12-04 2018-12-07 霍夫曼-拉罗奇有限公司 心力衰竭疗法的选择中的生物标记物

Also Published As

Publication number Publication date
ES2824110T3 (es) 2021-05-11
AU2012324967A8 (en) 2014-03-20
BR112014007007B1 (pt) 2022-04-19
AU2012324967B2 (en) 2015-09-17
EP3088900B1 (en) 2020-08-12
US20170023588A1 (en) 2017-01-26
AU2012324967A1 (en) 2014-03-13
JP6117805B2 (ja) 2017-04-19
SG2014014559A (en) 2014-08-28
EP3088900A1 (en) 2016-11-02
EP2769227A1 (en) 2014-08-27
KR101950561B1 (ko) 2019-02-20
HK1196158A1 (zh) 2014-12-05
KR101643147B1 (ko) 2016-07-27
BR112014007007A2 (pt) 2017-04-11
JP2017049267A (ja) 2017-03-09
US11047865B2 (en) 2021-06-29
KR20160090913A (ko) 2016-08-01
EP2769227B1 (en) 2016-07-27
BR122021026652B1 (pt) 2022-08-23
WO2013057135A1 (en) 2013-04-25
US20140220604A1 (en) 2014-08-07
JP6412085B2 (ja) 2018-10-24
US20180196066A1 (en) 2018-07-12
US20160011210A1 (en) 2016-01-14
CA2846285C (en) 2019-09-24
JP2014535047A (ja) 2014-12-25
CA2846285A1 (en) 2013-04-25
CN103998938A (zh) 2014-08-20
CN105785053B (zh) 2018-09-21
ES2595028T3 (es) 2016-12-27
MX2014003496A (es) 2014-07-14
CN103998938B (zh) 2016-06-15
KR20140059864A (ko) 2014-05-16
CN105785053A (zh) 2016-07-20

Similar Documents

Publication Publication Date Title
MX347355B (es) Diagnostico basado en troponina y en peptido natriuretico cerebral (bnp) de pacientes en riesgo y de causa de ataque.
EA201391187A1 (ru) Способ диагностики злокачественной опухоли и набор для диагностики путем измерения активности nk-клеток
PL2986735T3 (pl) Sposób określania składu ilościowego komórek krwi w próbce
ECSP14010817A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
IN2014CN04326A (es)
WO2011092285A3 (en) Means and methods for diagnosing heart failure in a subject
WO2013033609A3 (en) Methods and compositions for the treatment and diagnosis of cancer
EA201590247A1 (ru) Антитела к siglec-15
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
IN2015DN00678A (es)
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
MX360479B (es) Anticuerpos contra microbioma, factores de estres y marcadores de mastocitos como marcadores de diagnostico para ibs.
WO2012094550A3 (en) Assays and methods of treatment relating to vitamin d insufficiency
MX2015008436A (es) Composiciones para permeabilizar celulas sanguineos fijos y sus usos.
EA201300817A1 (ru) Способ улучшенного приживления гемопоэтических стволовых клеток
NZ711543A (en) Anti-cd83 antibodies and use thereof
FI20115670A0 (fi) Kardiovaskulaarinen in vitro-malli
NZ729773A (en) Biomarkers for disease progression in melanoma
EP3489365A4 (en) COMPOSITION FOR PREDICTING THE RISK OR DIAGNOSING A METABOLIC SYNDROME OR DISORDERS ASSOCIATED WITH METABOLIC SYNDROME USING AN ORAL BACTERIAL COMMUNITY
WO2014179737A3 (en) Assays and methods of treatment relating to vitamin d insufficiency
EP2571504A4 (en) Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal
WO2014047442A3 (en) Biomarkers for assessing treatment of sialic acid deficiency diseases and conditions
WO2011085176A3 (en) Fret-based method for the determination of protein phosphatase and kinase activity
WO2011163639A3 (en) Cell aging as a unique biomarker of major depression

Legal Events

Date Code Title Description
FG Grant or registration